Figure 9C i–iii illustrate the change in relative Pmel17 expression as a function of time showing improved anti-tumor responses in Melan-A VLP vaccinated animals with maximal anti-tumor responses in vaccinated animals receiving lymphatic delivery of combination therapy by 18 d.p.i. In contrast to subcutaneous (s.c.)implants, there was little to no primary tumor implants to evaluate the TILs. This evidence concerns the gene MLANA and neoplasm.